COSCIENS Biopharma Inc. (CSCI) - Total Assets
Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) holds total assets worth $27.56 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore COSCIENS Biopharma Inc. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
COSCIENS Biopharma Inc. - Total Assets Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s total assets have evolved over time, based on quarterly financial data. See COSCIENS Biopharma Inc. book value and equity for net asset value and shareholders' equity analysis.
COSCIENS Biopharma Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
COSCIENS Biopharma Inc.'s total assets of $27.56 Million consist of 68.4% current assets and 31.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.7% |
| Accounts Receivable | $2.47 Million | 7.1% |
| Inventory | $2.69 Million | 7.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CSCI stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: COSCIENS Biopharma Inc.'s current assets represent 68.4% of total assets in 2024, an increase from 17.7% in 1996.
- Cash Position: Cash and equivalents constituted 46.7% of total assets in 2024, up from 5.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 32.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 7.7% of total assets.
COSCIENS Biopharma Inc. Competitors by Total Assets
Key competitors of COSCIENS Biopharma Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.28 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $504.51 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.78 Billion |
|
Savara Inc
NASDAQ:SVRA
|
USA | $253.44 Million |
COSCIENS Biopharma Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.98 | 3.36 | 3.93 |
| Quick Ratio | 2.65 | 3.05 | 3.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.97 Million | $23.31 Million | $5.27 Million |
COSCIENS Biopharma Inc. - Advanced Valuation Insights
This section examines the relationship between COSCIENS Biopharma Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 47.7% |
| Total Assets | $35.07 Million |
| Market Capitalization | $8.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values COSCIENS Biopharma Inc.'s assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: COSCIENS Biopharma Inc.'s assets grew by 47.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for COSCIENS Biopharma Inc. (1996–2024)
The table below shows the annual total assets of COSCIENS Biopharma Inc. from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $35.07 Million | +47.69% |
| 2023-12-31 | $23.75 Million | -14.60% |
| 2022-12-31 | $27.80 Million | +14.17% |
| 2021-12-31 | $24.35 Million | +6.26% |
| 2020-12-31 | $22.92 Million | +9.78% |
| 2019-12-31 | $20.88 Million | +12.27% |
| 2018-12-31 | $18.59 Million | -15.92% |
| 2017-12-31 | $22.11 Million | +12.62% |
| 2016-12-31 | $19.64 Million | +73.51% |
| 2015-12-31 | $11.32 Million | +70.98% |
| 2014-12-31 | $6.62 Million | +38.26% |
| 2013-12-31 | $4.79 Million | +22.55% |
| 2012-12-31 | $3.91 Million | -4.38% |
| 2011-12-31 | $4.09 Million | +44.89% |
| 2010-12-31 | $2.82 Million | +6.55% |
| 2009-12-31 | $2.65 Million | -2.04% |
| 2008-12-31 | $2.70 Million | -41.69% |
| 2007-12-31 | $4.63 Million | +161.76% |
| 2006-12-31 | $1.77 Million | -15.03% |
| 2005-12-31 | $2.08 Million | +45.75% |
| 2004-12-31 | $1.43 Million | +47.62% |
| 2003-12-31 | $968.03K | +136.15% |
| 2002-12-31 | $409.92K | +74.80% |
| 2001-12-31 | $234.50K | +19.54% |
| 2000-12-31 | $196.16K | -2.48% |
| 1999-12-31 | $201.16K | -38.10% |
| 1998-12-31 | $324.95K | -96.45% |
| 1997-12-31 | $9.15 Million | -32.55% |
| 1996-12-31 | $13.57 Million | -- |
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more